Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboxyamidotriazole in Advanced Renal Cell Carcinoma
NCT00005045Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2000
- Countries
- 3
- Sponsor
- Eastern Cooperative Oncology Group
- Modality
- Small Molecules
- Drugs
- carboxyamidotriazole
- Conditions
- renal cell carcinoma (RCC)
01
Overview
Phase 2, open-label, single-arm trial of carboxyamidotriazole in renal cell carcinoma (RCC), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Mar 2000; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Carboxyamidotriazole
Patients receive oral carboxyamidotriazole daily.
03
Who it enrols
Patients with histologically proven advanced renal cell carcinoma who are refractory to immunotherapy (1-2 prior biologic regimens), have measurable progressive disease, ECOG 0-2, and adequate organ function. Patients with brain metastases or prior chemotherapy are excluded.
04
Endpoints
Primary
Progression-Free Survival Rate
Secondary
Progression-Free Survival Rate
Objective Response Rate
Toxic Effect
Beyond the preview
Go deeper on NCT00005045.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005045.